Psychiatric Quarterly

, Volume 85, Issue 4, pp 487–496 | Cite as

No Change of The Lipid Profile Under The Control of ApoE Gene Polymorphism in Schizophrenics Under Paliperidone Treatment

  • Wei-Tsung Kao
  • Chen-Lin Chang
  • Yi-Lung Chen
  • For-Wey Lung
Original Paper


The present study tried to explore the effects of Paliperidone on the lipid profiles of schizophrenia patients. One hundred twenty-nine subjects diagnosed with schizophrenia were enrolled into this study and completed the lipid profile evaluation. Their blood samples were obtained on the morning following a 12-hours fast. Cholesterol and triglyceride (TG) levels in plasma were determined, and lipoproteins were determined by enzymatic methods. All participants provided written informed consent, and underwent additional venous blood withdrawal for DNA extraction for genetic study of the ApoE gene polymorphism. Under T test, TC, TG and HDL levels all declined after Paliperidone treatment although with no statistically significant difference. The ratios of TC/HDL declined after Paliperidone treatment, but without statistically significant difference. After GEE-I analysis, we found that ApoE4 genotype (β = 34.471; p < 0.001) had a positive effect on the total cholesterol (TC) level; female had positive effect on the high-density lipoprotein (HDL) level (β = 15.361; p = 0.003); and age had a positive effect on the TG level (β = 1.317; p = 0.030). Smoking (β = 0.961; p = 0.016) had a positive effect on the ratio of TC/HDL change. Lipid profiles were not increased after Paliperidone treatment under the control of ApoE gene polymorphism.


Paliperidone Schizophrenia ApoE gene polymorphism 



All authors would like to acknowledge all researchers in Kaohsiung Armed Forced Hospital who assisted in this study.


  1. 1.
    Jablensky A. Epidemiology of schizophrenia: the global burden of disease and disability. Eur Arch Psychiatry Clin Neurosci. 2000; 250: 274–85.PubMedCrossRefGoogle Scholar
  2. 2.
    Sussman N. Review of atypical antipsychotics and weight gain. J Clin Psychiatry. 2001; 62: 5–12.PubMedCrossRefGoogle Scholar
  3. 3.
    Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988; 37: 1595–1607.PubMedCrossRefGoogle Scholar
  4. 4.
    Littrell K, Petty R, Hilligoss N, Kirshner C, Johnson C, Ortega T, et al. Insulin resistance and syndrome X among schizophrenia patients. San Francisco, USA: Meeting of the American Psychiatry Association; 2003.Google Scholar
  5. 5.
    Heiskanen T, Niskanen L, Lyytikainen R, Saarinen PI, Hintikka J. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry. 2003; 64: 575–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Lund BC, Perry PJ, Brooks JM, Arndt S. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Arch General Psychiatry. 2001; 58: 1172–6.CrossRefGoogle Scholar
  7. 7.
    Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry. 2003; 160: 284–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Sasaki J, Kumagae G, Sata T, Kuramitsu M, Arakawa K. Decreased concentration of high density lipoprotein cholesterol in schizophrenic patients treated with phenothiazines. Atherosclerosis. 1984; 51: 163–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Mahley RW: Apolipoprotein E. cholesterol transport protein with an expanding role in cell biology. Science. 1988; 240: 622-30.PubMedCrossRefGoogle Scholar
  10. 10.
    Kamboh MI, Serjeantson SW, Ferrell RE. Genetic studies of human apolipoproteins. XVIII. Apolipoprotein polymorphisms in Australian Aborigines. Hum Biol. 1991; 63: 179-86.PubMedGoogle Scholar
  11. 11.
    Sing CF, Davignon J. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet. 1985; 37: 268-85.PubMedCentralPubMedGoogle Scholar
  12. 12.
    Boerwinkle E, Utermann, G. Simultaneous effects of the apolipoprotein E polymorphism, apolipoprotein B, and cholesterol metabolism. Am J Hum Genet. 1988; 42: 104-12.PubMedCentralPubMedGoogle Scholar
  13. 13.
    Eggersten G, Tegelman R, Ericsson S, Angelin B, Berglund L. Apolipoprotein E polymorphism in a healthy Swedish population: Variation of allele frequency with age and relation to serum lipid concentrations. Clin Chem. 1993; 39: 2125-9.Google Scholar
  14. 14.
    Luc G, Bard JM, Arveiler D, Evans A, Cambou JP, Bingham A, et al. Impact of apolipoprotein E polymorphism on lipoproteins and risk of myocardial infarction: the ECTIM Study. Arterioscler Thromb. 1994; 14: 1412-9.PubMedCrossRefGoogle Scholar
  15. 15.
    Schaefer EJ, Lamon-Fava S, Johnson S, Ordovas JM, Schaefer MM, Castelli WP, Wilson PW. Effects of gender and menopausal status on the association of apolipoprotein E phenotype with plasma lipoprotein levels. Results from the Framingham Offspring Study. Arterioscler Thromb. 1994; 14: 1105-3.PubMedCrossRefGoogle Scholar
  16. 16.
    Muros M, Rodriguz-Ferrer C. Apolipoprotein E polymorphism influence on lipids, apolipoproteins and Lp(a) in a Spanish population underexpression ApoE4. Atherosclerosis. 1996; 121: 13-21.PubMedCrossRefGoogle Scholar
  17. 17.
    Gomez-Coronado D, Alvarez JJ, Entrala A, Olmos JM, Herrera E, Lasuncion MA. Apolipoprotein E polymorphism in men and women from a Spanish population: allele frequencies and influence on plasma lipids and apolipoproteins. Atherosclerosis. 1999; 147: 167-76.PubMedCrossRefGoogle Scholar
  18. 18.
    Larson IA, Ordovas JM, DeLuca C, Barnard JR, Feussner G, Schaefer EJ. Association of apolipoprotein (Apo)E genotype with plasma ApoE levels. Atherosclerosis. 2000; 148: 327-35.PubMedCrossRefGoogle Scholar
  19. 19.
    Hsueh WC, Mitchell BD, Hixson JE, Rainwater DL. Effects of the ApoE polymorphism on plasma lipoproteins in Mexican Americans. Ann Epidemiol. 2000; 8: 524-31.CrossRefGoogle Scholar
  20. 20.
    Geelen A, Zock PL, DeVries JHM, Katan MB. Apolipoprotein E polymorphism and serum lipid response to plant sterol in humans. Eur J Clin Invest. 2002; 32: 738-42.PubMedCrossRefGoogle Scholar
  21. 21.
    Marques-Vidal P, Bongard V, Ruidavets JB, Fauvel J, Hanaire-Broutin H, Perret B, Ferrieres J. Obesity and alcohol modulate the effect of Apolipoprotein E polymorphism on lipids and insulin. Obes Res. 2003; 11: 1200-6.PubMedCrossRefGoogle Scholar
  22. 22.
    Braeckman L, De Bacquer D, Rosseneu M, De Backer G. Apolipoprotein E polymorphism in middle-aged Belgian men: phenotype distribution and relation to serum lipids and lipoproteins. Atherosclerosis. 1996; 120: 67-73.PubMedCrossRefGoogle Scholar
  23. 23.
    Mahley RW, Pepin J, Palaoglu KE, Malloy MJ, Kane JP, Bersot TP. Low levels of high density lipoproteins in Turks, a population with elevated hepatic lipase: high density lipoprotein characterization and gender-specific effects of apolipoprotein E genotype. J Lipid Res. 2000; 41: 1290-301.PubMedGoogle Scholar
  24. 24.
    Balakrishnan S, Colling C, B urkman T, Erickson J, Lyden E, Maheshwari H, et al. Apolipoprotein E gene polymorphism alters lipids before pancreas transplantation. Transplantation. 2002; 74: 974-7.Google Scholar
  25. 25.
    Bednarska-Makaruk M, Broda G, Kurjata P, Rodo M, Roszcynko M, Rywik S, Wehr H. Apolipoprotein E genotype, lipid levels and coronary heart disease in a Polish population group. Eur J Epidemiol. 2001; 17: 789-92.PubMedCrossRefGoogle Scholar
  26. 26.
    Barbagallo CM, Polizzi F, Severino M, Rizzo M, Vivona N, Onorato F, et al. ApoE polymorphism in a small Mediterranean island: Relationships with plasma lipids, lipoproteins and LDL particle size. Eur J Epidemiol. 2002; 17: 707-13.CrossRefGoogle Scholar
  27. 27.
    Pena R, Lahoz C, Mostaza JM, Jimenez J Subirates E, Pinto X, et al. Effect of apoE genotype on the hypolipidaemic response to pravastatin in an outpatient setting. J Intern Med. 2002; 251: 518-25.PubMedCrossRefGoogle Scholar
  28. 28.
    Leon AS, Togashi K, Rankinen T, Despres JP, Rao DC, Skinner JS, et al. Association of apolipoprotein E polymorphism with blood lipids and maximal oxygen uptake in the sedentary state and after exercise training in the HERITAGE Family Study. Metabolism. 2004; 53: 108-16.PubMedCrossRefGoogle Scholar
  29. 29.
    Eto M, Watanabe K, Ishi K. Reciprocal effects of apolipoprotein E alleles (e2 and e4) on plasma lipid levels in normolipidemic subjects. Clin Genet. 1986; 29: 477-84.PubMedCrossRefGoogle Scholar
  30. 30.
    Zaman MM, Ikemoto S, Yoshiike N, Date C, Yokoyama T, Tanaka H. Association of Apolipoprotein genetic polymorphisms with plasma cholesterol in a Japan rural population: the Shibata Study. Arterioscler Thromb Vasc Biol. 1997; 17: 3495-504.PubMedCrossRefGoogle Scholar
  31. 31.
    Katsuya T, Baba S, Ishikawa K, Mannami T, Fu Y, Inamoto N, et al. Epsilon 4 allele of apolipoprotein E gene associates with lower blood pressure in young Japanese subjects: the Suita Study. J Hypertens. 2002; 20: 2017-21.PubMedCrossRefGoogle Scholar
  32. 32.
    Tsunoda K, Harihara S, Dashnyam B, Semjidmann D, Yamaguchi Y, Tanabe Y, et al. Apolipoprotein E and H polymorphism in Mongolian Byrant: Allele frequencies and relationship with plasma lipid levels. Hum Biol. 2002; 74: 659-71.PubMedCrossRefGoogle Scholar
  33. 33.
    Heng CK, Saha N, Tay JSH. Lack of association of apolipoprotein E polymorphism with Lp(a) levels in the Chinese. Clin Genet. 1995; 48:113-9.PubMedCrossRefGoogle Scholar
  34. 34.
    Kao JT, Tsai KS, Chang CJ, Huang PC. The effects of apolipoprotein E polymorphism on the distribution of lipids and lipoproteins in the Chinese population. Atherosclerosis. 1995; 114: 55-9.PubMedCrossRefGoogle Scholar
  35. 35.
    Shen X, Xia Y, Sass C, Visvikis S, Siest G. Association of apolipoprotein E polymorphism and concentration with serum lipids and apolipoprotein level in the Chinese from Shanghai. Clin Chem Lab Med. 1998; 36: 615-9.PubMedCrossRefGoogle Scholar
  36. 36.
    Liu HC, Hong CJ, Wang SJ, Fuh JL, Wang PN, Shyu HY, Teng EL. ApoE genotype in relation to AD and cholesterol: a study of 2,236 Chinese adults. Neurology. 1999; 53: 962-6.PubMedCrossRefGoogle Scholar
  37. 37.
    Tan CE, Tai ES, Tan CS, Chia KS, Lee J, Chew SK, Ordovas JM. APOE polymorphism and lipid profile in three ethnic groups in the Singapore population. Atherosclerosis. 2003; 170: 253-60.PubMedCrossRefGoogle Scholar
  38. 38.
    Evans AE, Zhang W, Moreel JF, Bard JM, Ricard S, Poirier O, et al. Polymorphisms of the apolipoprotein B and E genes and their relationship to plasma lipid variables in healthy Chinese men. Hum Genet. 1993; 92: 191-7.PubMedCrossRefGoogle Scholar
  39. 39.
    Criqui MH, Golomb BA. Epidemiologic aspects of lipid abnormalities. Am J Med. 1998; 105(1A): 48S-57S.PubMedCrossRefGoogle Scholar
  40. 40.
    Chen YL, Cheng TS, Lung FW. Prolactin levels in Olanzapine treatment correlate with positive symptoms of schizophrenia: results from an open-label, flexible-dose study. Prim Care Companion J Clin Psychiatry. 2009; 11(1): 16-20.PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone. A novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994; 55(Suppl): 5-12.PubMedGoogle Scholar
  42. 42.
    Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000; 68: 29-39.PubMedCrossRefGoogle Scholar
  43. 43.
    Karlsson P, Dencker E, Nyberg S, Mannaert E, Boom S, Talluri K, et al. Pharmacokinetics and dopamine D2 and serotonin 5-HT2A receptor occupancy of Paliperidone in healthy subjects: Two open-label, single-dose studies. Clin Pharmacol Ther. 2006; 79: 74.CrossRefGoogle Scholar
  44. 44.
    Kozielska M, Johnson M, Reddy VP, Vermeulen A, Li C, Grimwood S, et al. Pharmacokinetic pharmacodynamic modeling of the D2 and 5-HT2A receptor occupancy of Risperidone and Paliperidone in rats. Pharm Res. 2012; 29: 1932-48.PubMedCentralPubMedCrossRefGoogle Scholar
  45. 45.
    Yang MC, Lung FW. Neuroprotection of Paliperidone on SH-SY5Y cells against β-amyloid peptide25-35, N-methyl-4-phenylpyridinium ion, and hydrogen peroxide-induced cell death. Psychopharmacology. 2011; 217(3): 397-410.PubMedCrossRefGoogle Scholar
  46. 46.
    Yang MC, Chen KP, Lung FW. Generalized estimating equation model and long-term exposure effect of antipsychotics on SH-SY5Y cells against oxidative stressors. Eur J Pharmacol. 2014; Available online.Google Scholar
  47. 47.
    Carter CJ. Schizophrenia susceptibility genes converge on interlinked pathways related to glutamatergic transmission and long-term potentiation, oxidative stress and oligodendrocyte viability. Schizophr Res. 2006; 86(1): 1-14.PubMedCrossRefGoogle Scholar
  48. 48.
    Fendri C, Mechri A, Khiari G, Othman A, Kerkeni A, Gaha L. Oxidative stress involvement in schizophrenia pathophysiology: a review. L’Encephale. 2005; 32(2 Pt 1): 244-52.Google Scholar
  49. 49.
    Ng F, Berk M, Dean O, Bush A I. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol. 2008; 11(06): 851-76.PubMedCrossRefGoogle Scholar
  50. 50.
    Bitanihirwe BK, Woo TUW. Oxidative stress in schizophrenia: an integrated approach. Neurosci Biobehav Rev. 2011; 35(3): 878-93.PubMedCentralPubMedCrossRefGoogle Scholar
  51. 51.
    Montine KS, Quinn JF, Zhang J, Fessel JP, Roberts II LJ, Morrow JD., Montine TJ. Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem Phys Lipids. 2004; 128(1): 117-24.PubMedCrossRefGoogle Scholar
  52. 52.
    Arlt S, Beisiegel U, Kontush A. Lipid peroxidation in neurodegeneration: new insights into Alzheimer’s disease. Curr Opin Lipidol. 2002; 13(3): 289-94.PubMedCrossRefGoogle Scholar
  53. 53.
    Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998; 59(suppl 20): 22-33.PubMedGoogle Scholar
  54. 54.
    Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986; 42(1): 121-30.PubMedCrossRefGoogle Scholar
  55. 55.
    Zhang Y, Dai G. Efficacy and metabolic influence of Paliperidone ER, aripiprazole and ziprasidone to patients with first‐episode schizophrenia through 52 weeks follow‐up in China. Hum Psychopharmacol. 2012; 27(6): 605-14.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Wei-Tsung Kao
    • 1
    • 2
  • Chen-Lin Chang
    • 1
    • 3
  • Yi-Lung Chen
    • 1
    • 4
  • For-Wey Lung
    • 2
    • 5
  1. 1.Department of PsychiatryKaohsiung Armed Forces General HospitalKaohsiungTaiwan
  2. 2.Graduate Institute of Medical ScienceNational Defense Medical CenterTaipeiTaiwan
  3. 3.Graduate Institute of MedicineKaohsiung Medical UniversityKaohsiungTaiwan
  4. 4.Department of Biological SciencesNational Sun Yat-sen UniversityKaohsiungTaiwan
  5. 5.Songde BranchTaipei City HospitalTaipeiTaiwan

Personalised recommendations